respi

  1. T

    Alnylam Publishes Results From Phase IIa Study Of ALN-RSV01 In The Treatment Of Respi

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company announced today that it has published results in the American Journal of Respiratory and Critical Care Medicine (Zamora et al., Am. J. Respir. Crit. Care Med., doi:10.1164/rccm.201003-0422OC, 2010) from its...
Back
Top